Abstract library

12 results for "Granberg".
#173 Temozolomide in Metastatic Bronchial Carcinoids
Introduction: Metastatic bronchial carcinoids are rare neoplasms, where efforts of medical treatment thus far have been disappointing. Temozolomide has, however, shown some activity in a small prior study.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Daniel P Lindholm
#178 Treatment with 177Lutetium-DOTA-Tyr3-octreotate in Patients with Neuroendocrine Tumors
Introduction: Neuroendocrine tumors express somatostatin receptors. Treatment with radiolabelled somatostatin analogs has been used for more than 10 years. Useful isotopes are 111Indium, 99Yttrium and 177Lutetium.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Ass Prof Dan Granberg
#196 Efficacy and Safety of the Combination Streptozotocin, 5-FU in Endocrine Pancreatic Tumors: A Retrospective Study
Introduction: The combination of Streptozotocin with 5-FU has been used during the past decades in our institution as the first-line treatment in pancreatic NETs with low to moderate proliferation.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Pantelis Antonodimitrakis
#209 A Randomized, Cross-Over Study in Patients with Neuroendocrine Tumors (NETs) to Assess Patient Preference of Lanreotide Autogel Given by Either Self/Partner or Healthcare Professional
Introduction: Ready-to-use Lanreotide Autogel provides the option of self/partner administration for patients with NET. This is anticipated to reduce treatment cost and negative impact on daily life.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MSc Anders Öhberg
#247 Carcinoid Metastases to the Breast: More Common than Previously Thought. A Presentation of 13 Cases
Introduction: Metastases from carcinoid tumors to the breast have been described as a rare phenomenon. Presentation and cytopathologic findings of these tumors can closely mimic that of a mammary carcinoma.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Joakim Crona
#434 Treatment, Survival and Prognostic Markers in Patients with Thymic Carcinoids: A Clinicopathologic Study of 28 Cases
Introduction: Thymic carcinoids are uncommon but malignant tumors, usually associated with a poor prognosis. The number of cases reported is limited to a few hundred and there are few prognostic factors available.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Joakim Crona
#493 Pasireotide and Octreotide LAR Was an Effective Combination in a Patient with Small Intestinal NET with Hypokalemia and a High Level of VIP
Introduction: Small Intestinal neuroendocrine tumors (NET) are argentaffin-positive tumors that progress slowly.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Gordana Kozlovacki
#503 Long-Term Stable Disease with Everolimus in a Patient with Advanced Pancreatic Neuroendocrine Tumor Enrolled in RADIANT-1
Introduction: The phase II open-label RADIANT-1 study evaluated the safety and efficacy of Everolimus (E, 10 mg/d) ± octreotide LAR (O) in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET) after chemotherapy failure. Objective tumor response was 9.6% in the E group and 4.4% in the E+O group (all partial), and stable disease (SD) was 68% and 80%.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Jenny Falkerby
#658 Somatic Mutations in H-RAS in Sporadic Pheochromocytoma and Paraganglioma Identified by Exome Sequencing.
Introduction: Up to 60% of pheochromocytoma (PCC) and paraganglioma (PGL) are associated with mutations in established PCC and PGL susceptibility loci. A majority of unexplained cases are characterized by an increased activity of the RAS/RAF/ERK signalling pathway. Mutations in RAS subtypes H, K and N are common in human cancers, however, previous studies have been inconsistent regarding the mutational status of RAS in PCC and PGL.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Joakim Crona
#861 Targeted Next Generation Sequencing in the Screening for Familial Neuroendocrine Tumor Syndromes: A Tool for Personalized Medicine
Introduction: Multiple syndromes are described as conferring susceptibility to NETs; MEN1 & 2, NF1, familial PGL 1-5, TSC, VHL and germline mutations in the HIF2A, MAX, or TMEM127. Genetic testing covering these diagnoses may be extensively resource-demanding using traditional techniques due to the large extent of these loci.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Joakim Crona
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.